现代临床医学
現代臨床醫學
현대림상의학
JOURNAL OF MODERN CLINICAL MEDICINE
2015年
3期
11-14
,共4页
代谢综合征%糖脂平%胰岛素敏感性%炎症因子
代謝綜閤徵%糖脂平%胰島素敏感性%炎癥因子
대사종합정%당지평%이도소민감성%염증인자
metabolic syndrome%Tangzhiping%insulin sensitivity%inflammatory factor
目的:观察糖脂平对代谢综合征( MS)患者胰岛素敏感性及超敏C反应蛋白( hs-CRP)和肿瘤坏死因子α( TNF-α)的影响。方法采用随机平行对照的方法将符合入选标准的70例MS者分为治疗组35例、对照组35例,治疗组在原治疗的基础上给予中药糖脂平汤药口服,对照组在原治疗的基础上给予罗格列酮口服。观察2组治疗前后胰岛素作用指数( IAI )、胰岛素抵抗指数( HOMA-IR)、hs-CRP和TNF-α的变化情况。结果完成临床试验的65例中,治疗组33例,对照组32例。治疗后2组的IAI水平均升高,与本组治疗前比较,差异均有统计学意义( P<0.01);组间比较差异无统计学意义( P>0.05)。治疗后2组的HOMA-IR水平均下降,与本组治疗前比较,差异均有统计学意义(P<0.01);组间比较差异无统计学意义(P>0.05)。治疗前2组的hs-CRP均有轻度升高,治疗后2组的hs-CRP均较本组治疗前明显降低( P<0.01);治疗前后组间比较差异均无统计学意义( P>0.05)。治疗后2组的TNF-α水平均明显降低,与本组治疗前比较,差异均有统计学意义(P<0.01);治疗后组间比较差异无统计学差异(P>0.05)。结论糖脂平可有效改善MS患者的胰岛素敏感性,同时可以降低炎症因子hs-CRP和TNF-α的水平。
目的:觀察糖脂平對代謝綜閤徵( MS)患者胰島素敏感性及超敏C反應蛋白( hs-CRP)和腫瘤壞死因子α( TNF-α)的影響。方法採用隨機平行對照的方法將符閤入選標準的70例MS者分為治療組35例、對照組35例,治療組在原治療的基礎上給予中藥糖脂平湯藥口服,對照組在原治療的基礎上給予囉格列酮口服。觀察2組治療前後胰島素作用指數( IAI )、胰島素牴抗指數( HOMA-IR)、hs-CRP和TNF-α的變化情況。結果完成臨床試驗的65例中,治療組33例,對照組32例。治療後2組的IAI水平均升高,與本組治療前比較,差異均有統計學意義( P<0.01);組間比較差異無統計學意義( P>0.05)。治療後2組的HOMA-IR水平均下降,與本組治療前比較,差異均有統計學意義(P<0.01);組間比較差異無統計學意義(P>0.05)。治療前2組的hs-CRP均有輕度升高,治療後2組的hs-CRP均較本組治療前明顯降低( P<0.01);治療前後組間比較差異均無統計學意義( P>0.05)。治療後2組的TNF-α水平均明顯降低,與本組治療前比較,差異均有統計學意義(P<0.01);治療後組間比較差異無統計學差異(P>0.05)。結論糖脂平可有效改善MS患者的胰島素敏感性,同時可以降低炎癥因子hs-CRP和TNF-α的水平。
목적:관찰당지평대대사종합정( MS)환자이도소민감성급초민C반응단백( hs-CRP)화종류배사인자α( TNF-α)적영향。방법채용수궤평행대조적방법장부합입선표준적70례MS자분위치료조35례、대조조35례,치료조재원치료적기출상급여중약당지평탕약구복,대조조재원치료적기출상급여라격렬동구복。관찰2조치료전후이도소작용지수( IAI )、이도소저항지수( HOMA-IR)、hs-CRP화TNF-α적변화정황。결과완성림상시험적65례중,치료조33례,대조조32례。치료후2조적IAI수평균승고,여본조치료전비교,차이균유통계학의의( P<0.01);조간비교차이무통계학의의( P>0.05)。치료후2조적HOMA-IR수평균하강,여본조치료전비교,차이균유통계학의의(P<0.01);조간비교차이무통계학의의(P>0.05)。치료전2조적hs-CRP균유경도승고,치료후2조적hs-CRP균교본조치료전명현강저( P<0.01);치료전후조간비교차이균무통계학의의( P>0.05)。치료후2조적TNF-α수평균명현강저,여본조치료전비교,차이균유통계학의의(P<0.01);치료후조간비교차이무통계학차이(P>0.05)。결론당지평가유효개선MS환자적이도소민감성,동시가이강저염증인자hs-CRP화TNF-α적수평。
Objective To observe the effect of Tangzhiping on insulin sensitivity, high sensitive C reactive protein ( hs-CRP ) and tumor necrosis factor-α( TNF-α) in patients with metabolic syndrome ( MS) .Methods 70 MS patients who met with defined criteria were randomly divided into treatment group (n=35) and control group (n=35).Besides the original treatment,Tangzhiping and rosiglitazone were given to the treatment group and control group separately for 12 weeks.Insulin action index ( IAI) , insulin resistance index ( IRI ) , hs-CRP and TNF-αwere observed before and after treatment in two groups.Results There were 65 patients fulfilled this trial, among which 33 were treated with Tangzhiping, and 32 were treated with rosiglitazone.IAI were all increased significantly in two groups than those before treatment(P <0.01).There was no statistical significance between two groups(P>0.05).IR were all decreased in both groups than those before treatment ( P<0.01).There was no statistical significance between two groups(P>0.05).The levels of hs-CRP were all higher than the reference value in two groups before treatment.The level of hs-CRP were all decreased in two groups than those before treatment ( P<0 .01 ) , but there was no statistical significance between two groups ( P>0.05).The level of TNF-αwere all decreased in two groups than those before treatment (P<0.01), but there was no statistical significance between two groups( P >0.05).Conclusions Tangzhiping could improve insulin sensitivity of patient with MS.It could also decrease the levels of hs-CRP and TNF-α.